SMMT241220C16500
- 1.65
- 0.000.00%
Summit Therapeutics Newsroom
Summit Therapeutics Initiated at Overweight by Wells Fargo
Wells Fargo Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $30
Summit Therapeutics Analyst Ratings
Jefferies Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Summit Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target
Strategic Position and Acquisition Interest Bolster Buy Rating for Summit Therapeutics
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
Buy Rating Affirmed for Summit Therapeutics Amid Promising Clinical Trials and Regulatory Progress
Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23
Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19